Zoetis' Go-to-Market Reset: Defending Share at the Cost of Growth
Competitive pressure and pet-owner affordability force a strategic pivot, slashing guidance and triggering leadership changes.
ZTS · Earnings Call · 2026-08-06
The Inflection Point
Zoetis' second-quarter report marked a clear strategic reset. Revenue fell 1% organically — the first decline in recent memory — and the company slashed full-year guidance to organic revenue growth of -3% to -1%. The headline driver is a competitive environment in companion animal that has turned from expansionary to share‑grabbing. On the call, CEO Kristin Peck described the new reality:This is a fundamental change from prior quarters, where competitors helped grow the market. Now, with therapeutic visits declining in the U.S. and a persistent pet owner affordability squeeze, Zoetis is playing defense.New entrants are using higher levels of discounting, rebates, cross-portfolio bundling, and other incentives to compete for existing patients.
Price to Revenue has collapsed from a peak of 14.8x to 5.2x, reflecting the market's re‑rating of the growth story. The stock's 90‑day return is -34%, with a drawdown of -36.7% — a dramatic de‑rating for a company that had been a consistent compounder.
Defending the Franchise
The most significant tactical shift is the move away from list price increases toward gross‑to‑net investments. CFO Wetteny Joseph explained: “we took select targeted actions across various franchises, gross-to-net investments in Dermatology, and price adjustments on Cerenia and Convenia in the US in response to generic competition.” — Wetteny Joseph, Chief Financial Officer · 2026-08-06 These actions are designed to protect volume and share, but they come at the expense of price realization and margins. The company is also stepping up promotional activity and direct‑to‑consumer spending at point of sale, as Peck noted: “our real focus around gross-to-net pricing investments … is really focused on our goal, which is how do we maintain our volume or gain it.” — Kristin Peck, Chief Executive Officer · 2026-08-06 While management frames this as a time‑bound defense, the intensity of competition and the persistence of end market demand weakness suggest the pressure may extend into 2027.The pain is concentrated in the U.S. companion animal portfolio, where revenue fell 11%, and Key Derm dropped 18%. net investments in the franchise are aimed at defending Apoquel and Cytopoint, but share is eroding — the company disclosed that its in-clinic Derm share fell 10 points year‑over‑year to roughly 86%. Even the previously unassailable Simparica franchise saw U.S. revenue down 6%, as flea, tick, and heartworm visits declined 7%.
A Split Business
Yet the portfolio is bifurcating. Livestock delivered 11% growth, led by cattle and poultry, and diagnostics grew 12% on the back of urgent‑care demand. International segments grew 6%, with emerging markets a bright spot. This diversification is the cushion that lets management argue the long‑term thesis remains intact, but it does not offset the magnitude of the companion animal decline.The leadership shakeup — a new EVP of U.S. Commercial Operations and a newly created CFO/COO role — signals the board's urgency. Peck reiterated confidence in the pipeline, including long‑acting Cytopoint and the OA pain launches of Lenvia and Portela, but the near‑term is about navigating Feline OA pain and other categories under value‑conscious pressure.
This is not the first time Zoetis has faced competitive headwinds — as recently as May 2026, management downplayed the macro impact: “essentially, what we saw in the quarter was sort of the economic and sustained price increases that the pet owner has experienced in the clinic.” — Kristin Peck, Chief Executive Officer · 2026-05-07 But the current quarter shows the dynamics have escalated well beyond what was anticipated. The company is now explicitly assuming the market does not get easier, and guidance embeds a scenario where competitive pressures accelerate.
The question investors face is whether this is a cyclical trough or a structural repricing of the animal health premium. The 90‑day price action suggests the market is betting on the latter, at least for now.
We're going to be aggressive in defending our share and protecting our market share … we're assuming the competitive environment that we're operating in and some of the macro challenges.